biomedicines

IMPACT FACTOR 3.9

Indexed in: PubMed

CITESCORE 5.2

an Open Access Journal by MDPI

Feature Papers in Gene and Cell Therapy

Collection Editor:

Dr. Bernard Lebleu
Laboratory of Pathogen Host Interactions, Biology-Health Department, Montpellier University, Montpellier, France

Message from the Collection Editor

Recent progresses in gene and cell therapies have been the incentive for this *Biomedicine* «Feature Papers in Gene and Cell Therapy» Topical Collection. Contributions from the editorial board members, as well as from distinguished scholars in this rapidly growing field will be acknowledged.

Among the recent achievements in the field of gene therapy, CRISPR-directed gene edition has now reached clinical translation, with promising data in the treatment of sickle-cell anemia and thransthyrethin amyloidosis.

Contributions addressing fundamental or clinical researches dealing with nucleic acids-based strategies from oligonucleotides to mRNAs and DNAs, as well as key issues on viral or non-viral delivery vectors will be welcomed.

Cell therapy-based strategies also offer a great potential for the treatment of human diseases. As an example, pluripotent stem cells can be generated from somatic cells with the capacity to proliferate indefinitely and to be reprogrammed for differentiation at will.

Contributions dealing with various aspects and applications of cell-based strategies will be welcomed, from animal models to human diseases clinical studies.

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 5.2

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI